Analyst deems Novo Nordisk once-weekly insulin has blockbuster potential
Even so, the analyst from Danish bank Sydbank doesn’t think insulin icodec will reach the same level as the pharmaceutical giant’s popular GLP-1 drugs.
by marketwire, translated by daniel pedersen
Novo Nordisk’s experimental new type 2 diabetes insulin icodec has the potential to reach blockbuster heights, which is achieved once a drug generates more than USD 1bn within a financial year, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
